New drug INCA036873 enters human trials for Hard-to-Treat cancers
NCT ID NCT07195916
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 41 times
Summary
This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug through an IV, and researchers will monitor side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
NOT_YET_RECRUITINGAarhus, 08200, Denmark
-
Aou Policlinico S. Orsola-Malpighi
NOT_YET_RECRUITINGBologna, 40138, Italy
-
Cancer Research Sa
RECRUITINGAdelaide, South Australia, 05000, Australia
-
Centro Ricerche Cliniche Di Verona
NOT_YET_RECRUITINGVerona, 37134, Italy
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Cliniques Universitaires Ucl Saint-Luc
NOT_YET_RECRUITINGBrussels, 01200, Belgium
-
Fondazione Irccs Istituto Nazionale Dei Tumori
NOT_YET_RECRUITINGMilan, 20133, Italy
-
Macquarie University Hospital
RECRUITINGSydney, New South Wales, 02109, Australia
-
Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10021, United States
-
Peter Maccallum Cancer Centre-Royal Melbourne Hospital
RECRUITINGMelbourne, Victoria, 03000, Australia
-
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
NOT_YET_RECRUITINGRome, 00168, Italy
-
Princess Alexandra Hospital Australia
RECRUITINGWoolloongabba, Queensland, 04102, Australia
-
Rigshospitalet Uni of Hospital of Copenhagen
NOT_YET_RECRUITINGCopenhagen, DK-2100, Denmark
-
Scri Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
The University of Nebraska Medical Center
NOT_YET_RECRUITINGOmaha, Nebraska, 68198, United States
-
Universitair Ziekenhuis Antwerpen
NOT_YET_RECRUITINGEdegem, 02650, Belgium
-
Universitair Ziekenhuis Gent (Uz Gent)
NOT_YET_RECRUITINGGhent, 09000, Belgium
-
Universitair Ziekenhuis Leuven
NOT_YET_RECRUITINGLeuven, 03000, Belgium
-
University of California San Diego Medical Center, Moores Cancer Center
NOT_YET_RECRUITINGLa Jolla, California, 92037, United States
-
University of Michigan
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Vanderbilt Medical Center
NOT_YET_RECRUITINGNashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCA036873 (an experimental drug given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors and certain blood cancers that have not responded to prior therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects. Only a small number of participants will receive the optimal dose.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.